ERBB2 and cancer: Furthermore, the overexpression of SLC2A1 seems to be necessary for the drug-resistant target HER2 to promote tumor drug resistance; ENO1 further affects cancer metabolism microenvironment through the crosstalk between glycolytic and phospholipid-synthesizing enzymes, promoting drug resistance and tumor cell proliferation (15, 16).